Department of Chemical Engineering and Biointerface Institute, University of Michigan, 2800 Plymouth Road, NCRC B10-A184, Ann Arbor, MI 48109, USA.
Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Lab Chip. 2022 Sep 13;22(18):3314-3339. doi: 10.1039/d2lc00232a.
Extracellular vesicles (EVs) have been hypothesized to incorporate a variety of crucial roles ranging from intercellular communication to tumor pathogenesis to cancer immunotherapy capabilities. Traditional EV isolation and characterization techniques cannot accurately and with specificity isolate subgroups of EVs, such as tumor-derived extracellular vesicles (TEVs) and immune-cell derived EVs, and are plagued with burdensome steps. To address these pivotal issues, multiplex microfluidic EV isolation/characterization and on-chip EV engineering may be imperative towards developing the next-generation EV-based immunotherapeutics. Henceforth, our aim is to expound the state of the art in EV isolation/characterization techniques and their limitations. Additionally, we seek to elucidate current work on total analytical system based technologies for simultaneous isolation and characterization and to summarize the immunogenic capabilities of EV subgroups, both innate and adaptive. In this review, we discuss recent state-of-art microfluidic/micro-nanotechnology based EV screening methods and EV engineering methods towards therapeutic use of EVs in immune-oncology. By venturing in this field of EV screening and immunotherapies, it is envisioned that transition into clinical settings can become less convoluted for clinicians.
细胞外囊泡 (EVs) 被假设具有多种重要作用,从细胞间通讯到肿瘤发病机制到癌症免疫治疗能力。传统的 EV 分离和表征技术不能准确和特异性地分离 EV 的亚群,如肿瘤衍生的细胞外囊泡 (TEVs) 和免疫细胞衍生的 EVs,并且存在繁琐的步骤。为了解决这些关键问题,多重微流控 EV 分离/表征和芯片上 EV 工程可能对于开发下一代基于 EV 的免疫疗法至关重要。因此,我们的目的是阐述 EV 分离/表征技术的最新进展及其局限性。此外,我们试图阐明基于总分析系统的技术的当前工作,用于同时分离和表征,并总结 EV 亚群的免疫原性,包括先天和适应性。在这篇综述中,我们讨论了基于微流控/微纳技术的最新 EV 筛选方法和 EV 工程方法,以用于免疫肿瘤学中 EV 的治疗用途。通过涉足 EV 筛选和免疫疗法领域,可以设想临床医生的临床应用过程会变得不那么复杂。